Skip to main content
TG THERAPEUTICS, INC. logo

TG THERAPEUTICS, INC. — Investor Relations & Filings

Ticker · TGTX ISIN · US88322Q1085 LEI · 529900X21UKABN9NJ529 US Manufacturing
Open in API
Filings indexed 1,012 across all filing types
Latest filing 2019-06-14 Director's Dealing
Country US United States of America
Listing US TGTX

About TG THERAPEUTICS, INC.

https://www.tgtherapeutics.com/

TG Therapeutics, Inc. is a fully integrated, commercial-stage biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases. The company's primary area of focus is autoimmune diseases, particularly multiple sclerosis (MS). Its lead commercial product is BRIUMVI® (ublituximab), an approved therapy for adults with relapsing forms of MS. TG Therapeutics also develops a pipeline of potential therapies for B-cell malignancies and other autoimmune conditions, including investigational CAR-T cell therapies.

Recent filings

Filing Released Lang Actions
FORM4
Director's Dealing
2019-06-14 English
8-K
Declaration of Voting Results & Voting Rights Announcements Classification · 100% confidence The document is a Form 8-K filed with the SEC, dated June 13, 2019, reporting the submission of matters to a vote of security holders at the company's annual meeting. It details the voting results on various proposals including election of directors, appointment of auditors, advisory votes on executive compensation, and a shareholder proposal. The content focuses on the official results of shareholder votes at the annual meeting. The document is not a full annual report, earnings release, or management discussion, but specifically reports voting outcomes. Therefore, it fits the category of Declaration of Voting Results & Voting Rights Announcements (DVA). The document length is 5432 characters, which is sufficient to contain detailed voting results rather than just an announcement of a report publication or a brief notice.
2019-06-13 English
Major Shareholding Notification 2019
Major Shareholding Notification
2019-06-07 English
PX14A6G
Proxy Solicitation & Information Statement Classification · 95% confidence The document is a solicitation letter from CalPERS to shareholders of TG Therapeutics, Inc. urging support for a shareholder proposal (#5) regarding majority voting for director elections at the upcoming Annual General Meeting (AGM). It discusses governance concerns and requests votes but does not contain financial data, audit information, or official voting results. It is not a proxy statement itself but is related to shareholder voting and governance issues. The document is a written communication to shareholders about a proposal to be voted on at the AGM, which aligns with Proxy Solicitation & Information Statement (PSI) filings. The document length is under 5,000 characters and is a solicitation letter, not an announcement of a report or a report itself. Therefore, the best classification is PSI.
2019-05-31 English
10Q
Interim / Quarterly Report Q1 2019
2019-05-10 English
8-K
Earnings Release Classification · 95% confidence The document is a Form 8-K filed with the SEC, dated May 10, 2019, reporting the results of operations for the first quarter ended March 31, 2019. It mentions a press release announcing the financial results and an investor conference call to discuss the first quarter financial results and business outlook. The document itself does not contain detailed financial statements or substantive financial data but rather announces the results and references a press release. The length is 3031 characters, which is relatively short and consistent with an announcement rather than a full report. According to the rules, such a document is best classified as an Earnings Release (ER) since it is the initial announcement of quarterly financial results with key highlights only, and it includes a press release and conference call information related to earnings.
2019-05-10 English

Browse filings by year

25 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.